June 3, 2024
Min Read

Letter from our CEO: The New Curebase and Our Path Ahead

You probably haven’t heard much from Curebase since our strategic shift last year. We’ve been heads down busy since then, and I wanted to share a bit about what we’ve been up to and where we’re taking the company next.

So what have we been up to?

Curebase has been building the next-generation version of our SaaS platform.

And we are now taking it back to market with a flagship ePRO/eCOA offering. We’ve been diligent and focused for 9 months, in which time I’ve gone back in with the team, taken our learnings from the DCT days, and focused on a few key investments:

Modern, global-ready eCOA

Data collection from participants and site staff is the anchor of our new platform. There is no patient-centricity without amazing data collection.

Familiar, intuitive participant experience

We see a unified, digital participant experience as the biggest need in clinical trial SaaS. No one has solved it yet, and succeeding means improving compliance and retention while expanding access to research. The experience includes eConsent, appointment management, participant education, engagement, notifications, empowered access to your own data, and more.

Powerful configurability

We’ve gone back to the drawing board on our study designer, with an all-new interface to craft and design the entire study experience, from patient onboarding to data collection, consenting, and site experience. We’ve built with user experience in mind to create rapid launches of the most complex designs. Every aspect of the trial can be configured, and we are offering both self-service offering and implementation services.

A well-rounded experience for sites

We learned that there is no participant experience without an intuitive site experience. That’s why Curebase offers site staff a clear line of sight into ePRO activities, with the same focus on simplicity and ease of use. Additionally, we are continuing to support and advance our EDC offering, for customers who would like data on a single platform, while also investing in clinical data integrations. 

What does change mean for Curebase?

For over 5 years, we were running a complex tech-enabled, digital CRO business. We helped dozens of customers enroll and manage tens of thousands of participants with a team of over 100 dedicated people, and grew the company through our Series B.

However, we realized our biggest strength was our software, and there was so much more value to unlock. It turns out that building clinical trial software and running a CRO at the same time is really hard, and we knew that we would need 100% focus on software to deliver on our vision.

There are very few times when a company gets the opportunity to take a step back and spend 9 months solving big industry problems without sales and marketing driving the whole agenda. We took the chance to be diligent, put our heads down to focus on developing our next-gen product, with the close collaboration of our existing customers and industry advisors, all while leveraging our years of hard-won learnings to perfect our offering. 

And now we’re more excited than ever to share our platform with the clinical research world.

Looking to the future

I want to extend a heartfelt thank you to our customers, staff, advisors, investors and industry partners who have played a role in our company’s changes. Your unwavering support and belief in our vision have been instrumental in this journey. We are more excited than ever shaping the next chapter together.

If you’d like to discuss an upcoming clinical trial opportunity or simply want to connect, please reach out to me directly at tom@curebase.com. Let’s continue this journey together.